Asceneuron is a clinical stage biotech company focused on the development of orally bioavailable therapeutics for debilitating neurodegenerative disorders with high unmet medical needs: orphan tauopathies, Alzheimer’s and Parkinson’s disease.

Products, services, technology

Asceneuron has two clinical stage small molecule O-GlcNAcase inhibitors in development for the treatment of proteinopathies including one first in class for Parkinson’s disease, one best in class in Alzheimer’s disease and related disorders.

Location

1015 Lausanne, Switzerland

Facts & figures
  • Type of organization
    Private company
  • Year of foundation
    2012
  • Number of employees in Switzerland
    1-9
Key business